Illumina (ILMN) possesses promising opportunities to advance the next-generation sequencing ecosystem. Adverse macroeconomic challenges remain a major downside. The stock carries a Zacks Rank #3 (Hold) currently. Illumina is currently keeping up well with the goals to strengthen its foothold in the multi-billion gene sequencing worldwide market with some highly competitive products in its existing portfolio and pipeline. Further, the company is developing sample-to-answer solutions to catalyze adoption in t ...